Progression to EDSS ≥ 7.0
FIGURE 1 · Panel Progression_to_EDSS_7.0
Panel Progression_to_EDSS_7.0 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Patrick Vermersch, Sophie Arnould, Ralf Gold, Ludwig Kappos, Robert Fox, Amit Bar-Or, Bruce A C Cree, Soudeh Ansari, Daniela Piani Meier, Goeril Karlsson, Nicolas Rouyrre, Gavin Giovannoni
Eur J Neurol 33(6) e70659
BACKGROUND: Delaying time to requiring a wheelchair in people living with MS is an important treatment goal to maintain quality of life and guard against increased healthcare costs. In this post hoc analysis, the effects of siponimod versus placebo on time to sustained Expanded Disability Status Scale (EDSS) ≥ 7.0 over the core part of the Phase 3 EXPAND study were assessed. METHODS: The time to sustained EDSS ≥ 7.0 (time to requiring a wheelchair) was analysed for participants with secondary progressive multiple sclerosis (SPMS). Analyses were based on a While on Treatment (WOT) set that censored participants if entering open-label treatment. Subgroup analyses were conducted in participants with active versus non-active SPMS (defined based on pre-study/baseline criteria), and in participants with baseline EDSS 6.5. RESULTS: In the overall EXPAND population, siponimod reduced the risk of reaching sustained EDSS ≥ 7.0 (requiring a wheelchair) by 40% (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.41-0.88; p = 0.009) versus placebo; the reduction in risk was 51% (HR, 0.49; 95% CI, 0.29-0.81; p = 0.005) versus placebo in participants with active SPMS and 22% (HR, 0.78; 95% CI, 0.42-1.45; p = 0.437) in non-active SPMS. CONCLUSION: Siponimod reduced the risk of requiring a wheelchair in participants with SPMS versus participants receiving placebo, with a greater effect in those with active disease. Time to requiring a wheelchair is a highly relevant treatment goal and an important indicator of treatment effect in patients with SPMS.
4 个 Figure · 5 个 KM 面板
FIGURE 1 Percentage of participants with progression to EDSS ≥ 7.0 sustained until last observation in the core part——while on treatment (WOT). In the derivation of the Cox regression and Kaplan–Meier estimates, data were re‐weighted using IPW, such that the proportion of participants in the following subgroups (baseline EDSS < 5.5, 5.5–6.0, 6.5) was balanced between siponimod and placebo, and matched that of the overall population. Numbers at risk are not adjusted. CI, confidence interval; EDSS, Expanded Disability Status Scale; HR, hazard ratio; IPW, inverse probability weighting; WOT, while on treatment.
FIGURE 1 · Panel Progression_to_EDSS_7.0
Panel Progression_to_EDSS_7.0 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 Percentage of participants with progression to EDSS ≥ 7.0 sustained until last observation in the core part—subgroup of participants with baseline EDSS 6.5—while on treatment (WOT). After onset of progression, an EDSS of ≥ 7.0 was required until the end of the core part in order to include a given patient in this analysis. CI, confidence interval; EDSS, Expanded Disability Status Scale; HR, hazard ratio; KM, Kaplan–Meier; WOT, while on treatment.
FIGURE 2 · Panel Percentage_of_participants_with_progression_to_EDSS_7.0
Panel Percentage_of_participants_with_progression_to_EDSS_7.0 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 Percentage of participants with progression to EDSS ≥ 7.0—overall population (WOT; based on extrapolated and observed data). In the derivation of the Cox regression and Kaplan–Meier estimates, data were re‐weighted using IPW, such that the proportion of participants in the following subgroups (baseline EDSS < 5.5, 5.5–6.0, 6.5) were balanced between siponimod and placebo and matched that of the overall population. CP, core part; EDSS, Expanded Disability Status Scale; EP, extension part; HR, hazard ratio; IPW, inverse probability weighting; KM, Kaplan–Meier; WOT, while on treatment set.
FIGURE 3 · Panel Main_panel
Panel Main_panel 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE A1 Percentage of participants with progression to EDSS ≥ 7.0—overall population (WOT; based on extrapolated from multistate Markov model and observed data). The above analysis can be viewed from different perspectives: (1) observed data (KM) are useful to assess the validity of the multi‐state Markov model, (2) standard KM and the multi‐state model complement each other in that the observed data (KM) in the core part were mostly based on information from patients with EDSS 6.5 when extrapolation (Markov model) accounted for information from a lower EDSS score. In particular, extrapolation helps to infer the effect of siponimod on delaying wheelchair dependence in the overall SPMS population, including patients with a lower EDSS score. CP, core part; EDSS, Expanded Disability Status Scale; EP, extension part; KM, Kaplan–Meier; SPMS, secondary progressive multiple sclerosis.
FIGURE A1 · Panel Active_SPMS
Panel Active_SPMS 是同一 FIGURE A1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE A1 · Panel Non-active_SPMS
Panel Non-active_SPMS 是同一 FIGURE A1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。